Hepatitis C Virus (HVC) Positive Heart Grafts in HCV Negative Recipients

Loma Linda University (LLU)

Status: Completed

Conditions: Heart Failure

Treatments: Procedure: Procedure: Heart Transplantation

Study type: Interventional

Funder types: Other

Identifiers

NCT04452578

5190371

Details and patient eligibility

About

To provide proof-of-concept data on the efficacy/safety of transplanting HCV positive donor grafts in HCV negative heart recipients who are currently listed.

Enrollment: 2 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Male or female
• Age 18 and older
• Active on the transplant list
• Donor organ with Antibody and NAT (nucleic acid test) positive for HCV
• HCV negative recipient; this includes patients who never had HCV and those with HCV previously eradicated with antiviral therapy. The latter is defined as those with undetectable HCV viral load at least 3 months since stopping therapy.
• Willing and able to provide written informed consent or for those subjects where hepatic encephalopathy affects their ability to provide initial or ongoing consent, has an appropriate and legally-authorized representative willing and able to provide consent on behalf of the subject
• Patients listed for multiple organ transplant (heart and kidney or heart and liver) can be included based on agreement of non-cardiac organ transplant team

Exclusion criteria

• Participants co-infected with HIV
• Donor previously treated with an NS5a containing regimen (if treatment history of donor known)
• Known allergies or hypersensitivity to DAA or ribavarin
• Pregnancy and/or actively breastfeeding

Trial design

Primary purpose: Treatment

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

2 participants in 1 patient group

Experimental: Recipient of HCV positive heart graft

Experimental group

Description:

A single center, open-label, pilot study examining 10 adult HCV negative heart transplant subjects who will receive an HCV infected graft. Target start date for antiviral therapy will be within 3 months after heart transplantation.

Treatment:

Procedure: Procedure: Heart Transplantation